FDA Roundup: August 11, 2023
/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, the FDA issued an...
Source: prnewswire.com
Page 44 - Risk Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Risk Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Risk Evaluation Today - Breaking & Trending Today
U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted...
Source: prnewswire.com
Early, Appropriate Treatment for Postpartum Depression Can Help New Mothers
A variety of comorbid mood disorders often accompany this condition, including OCD and PTSD.
Source: pharmacytimes.com
J&J Broadens Scope in Multiple Myeloma, Winning FDA Approval for New Drug
Johnson & Johnson’s stable of multiple myeloma drugs has grown to five products with the FDA approval of Talvey. The bispecific antibody is the first in a new class of new drugs designed to go after the novel multiple myeloma target GPRC5D.
Source: medcitynews.com
VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML
Daiichi Sankyo today announced that VANFLYTA® is now available by prescription in the U.S. VANFLYTA is the first and only FLT3 inhibitor to be approved by the U.S. Food and Drug Administration ...
Source: marketscreener.com